Filtered By:
Cancer: Ductal Carcinoma

This page shows you your search results in order of date.

Order by Relevance | Date

Total 32 results found since Jan 2013.

A functional genetic screen for metabolic proteins unveils GART and the de novo purine biosynthetic pathway as novel targets for the treatment of luminal A ER α expressing primary and metastatic invasive ductal carcinoma
In conclusion, GART inhibition by LMX or other inhibitors of the de novo purine biosynthetic pathway could be a novel effective strategy for the treatment of primary and metastatic BCs.
Source: Frontiers in Endocrinology - April 18, 2023 Category: Endocrinology Source Type: research

The heparan sulphate proteoglycan Syndecan ‐1 (CD138) regulates tumour progression in a 3D model of ductal carcinoma in situ of the breast
In this study, we employed a siRNA knockdown approach in the DCIS model cell line MCF10A DCIS.com to investigate a potential connection between Sdc-1 and epithelial mesenchymal transition (EMT), proteolysis and the Rho kinase pathway. Analysis of gene expression data of the TNMplot.com database revealed that Sdc-1 expression was higher in primary breast tumours compared to metastases. The impact of Sdc-1-depletion on the cellular phenotype was investigated in a Matrigel-based three-dimensional cell culture model. Sdc-1 depletion resulted in the formation of larger spheroids and the formation of invasive protrusions. Applic...
Source: IUBMB Life - May 20, 2022 Category: Research Authors: Christopher D'Arcy, Clarissa Constanze Zimmermann, Nancy Adriana Espinoza ‐Sanchez, Burkhard Greve, Annika Schmidt, Ludwig Kiesel, Marie‐Kristin von Wahlde, Martin Götte Tags: SPECIAL ISSUE Source Type: research

Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer.
Abstract In the present study, we have explored the prognostic value of the Phosphofructokinase Platelet-type (PFKP) expression and its therapeutic relevance in metastatic breast cancer. PFKP immunohistochemistry was performed on Invasive ductal carcinomas (IDCs; n = 87) of breast, and its association with clinicopathological parameters were evaluated. Using online meta-analysis tools, PFKP's prognostic value was investigated in overall breast cancer as well as in triple negative subtype (TNBCs). For in vitro analysis, MDA-MB-231 cells model was used in order to elucidate mechanisms behind PFKP regulated gly...
Source: Experimental Cell Research - September 9, 2020 Category: Cytology Authors: Umar SM, Kashyap A, Kahol S, Mathur S, Gogia A, Deo SVS, Prasad CP Tags: Exp Cell Res Source Type: research

EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation in vitro.
CONCLUSIONS: EZH2 downregulation in combination with irradiation reduces PANC-1 and MIA PaCa-2 cell proliferation more than irradiation alone. This study affirms the role of EZH2 downregulation for radiosensitization in pancreatic cancer treatment. PMID: 32161011 [PubMed - in process]
Source: Annals of Clinical and Laboratory Science - December 31, 2019 Category: Laboratory Medicine Authors: Agrawal R, Chen M, Bukhari Z, Ogunwobi OO, Haseeb MA, Martello LA Tags: Ann Clin Lab Sci Source Type: research

High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer
In this study, the immunohistochemistry results demonstrated that DEPDC1 was high-expressed in breast cancer tissues compared with the paired adjacent normal breast tissues, and its tendency at protein level was consistent with mRNA level from TCGA data. Moreover, DEPDC1 mRNA level revealed the strongest association with poor prognosis and development in breast cancer. In vitro assays showed that DEPDC1 overexpression resulted in significant promotion of proliferation by regulating cell cycle in MCF-7 cells, whilst an opposite effect was found in the MDA-MB-231 cells with DEPDC1 deletion. Notably, further investigation ind...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

OTOR in breast carcinoma as a potent prognostic predictor correlates with cell proliferation, migration and invasion.
This study aimed to investigate clinicopathologic significance of OTOR in breast infiltrating ductal carcinoma (IDC) with high metastasis and unveil its biological function in BC. OTOR was highly overexpressed in BC tissues and cells compared with normal samples. OTOR overexpression was associated with a few of clinicopathologic characteristics and worse overall survival (OS) of IDC breast patients. Silencing of OTOR using siRNA tool impeded BC cells proliferation, migration and invasion by CCK-8, colony formation, wound-healing and transwell assays, which might be regulated by mitogen-activated protein kinase/extracellula...
Source: Biochemistry and Cell Biology - March 20, 2019 Category: Biochemistry Authors: Wang YF, Han J Tags: Biochem Cell Biol Source Type: research

Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis
It is well known that comedo necrosis is closely associated with an aggressive phenotype of ductal carcinoma in situ (DCIS) of human breast, but its molecular mechanisms remain largely unclear. Therefore, in this study, we first examined the gene expression profile of comedo DCIS based on microarray data and identified CYC1 as a gene associated with comedo necrosis. Cytochrome c1 (CYC1) is a subunit of complex III in the mitochondrial oxidative phosphorylation that is involved in energy production. However, the significance of CYC1 has not yet been examined in DCIS. We therefore immunolocalized CYC1 in 47 DCIS cases. CYC1 ...
Source: Cancer Science - May 19, 2017 Category: Cancer & Oncology Authors: Mayuko Chishiki, Kiyoshi Takagi, Ai Sato, Yasuhiro Miki, Yuta Yamamoto, Akiko Ebata, Yukiko Shibahara, Mika Watanabe, Takanori Ishida, Hironobu Sasano, Takashi Suzuki Tags: Original Article Source Type: research

CYC1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis
This article is protected by copyright. All rights reserved.
Source: Cancer Science - March 1, 2017 Category: Cancer & Oncology Authors: Mayuko Chishiki, Kiyoshi Takagi, Ai Sato, Yasuhiro Miki, Yuta Yamamoto, Akiko Ebata, Yukiko Shibahara, Mika Watanabe, Takanori Ishida, Hironobu Sasano, Takashi Suzuki Tags: Original Article Source Type: research

TACC2 (transforming acidic coiled‐coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation
Abstract Transforming acidic coiled‐coil protein 2 (TACC2) belongs to TACC family proteins and involved in a variety of cellular processes through interactions with some molecules involved in centrosomes/microtubules dynamics. Mounting evidence suggests that TACCs is implicated in the progression of some human malignancies, but significance of TACC2 protein in breast carcinoma is still unknown. Therefore, in this study, we examined the clinical significance of TACC2 in breast carcinoma and biological functions by immunohistochemistry and in vitro experiments. Immunohistochemistry for TACC2 was performed in 154 cases of i...
Source: Cancer Medicine - June 21, 2016 Category: Cancer & Oncology Authors: Yoshiaki Onodera, Kiyoshi Takagi, Yasuhiro Miki, Ken‐ichi Takayama, Yukiko Shibahara, Mika Watanabe, Takanori Ishida, Satoshi Inoue, Hironobu Sasano, Takashi Suzuki Tags: Original Research Source Type: research

TACC2 (transforming acidic coiled ‐coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation
Abstract Transforming acidic coiled‐coil protein 2 (TACC2) belongs to TACC family proteins and involved in a variety of cellular processes through interactions with some molecules involved in centrosomes/microtubules dynamics. Mounting evidence suggests that TACCs is implicated in the progression of some human malignancies, but significance of TACC2 protein in breast carcinoma is still unknown. Therefore, in this study, we examined the clinical significance of TACC2 in breast carcinoma and biological functions by immunohistochemistry and in vitro experiments. Immunohistochemistry for TACC2 was performed in 154 cases of i...
Source: Cancer Medicine - June 21, 2016 Category: Cancer & Oncology Authors: Yoshiaki Onodera, Kiyoshi Takagi, Yasuhiro Miki, Ken ‐ichi Takayama, Yukiko Shibahara, Mika Watanabe, Takanori Ishida, Satoshi Inoue, Hironobu Sasano, Takashi Suzuki Tags: Original Research Source Type: research

Abstract PR06: Modeling the tumor microenvironment to identify novel loss of function mutations in breast cancer progression
Recent next generation sequencing studies have comprehensively mapped the genetic landscape of breast cancer and revealed that only a small number of genes are recurrently mutated in more than 10% of unselected tumors (i.e. TP53, PIK3CA and GATA3), and that the vast majority of recurrent mutations occur at low frequencies. Although some have been shown to be drivers (i.e. confer a selective advantage), such as oncogenic ERBB2 mutations, there is a myriad of significantly altered lower frequency mutations whose functional impact is unknown.We utilized a functional genomics approach silencing the 200 most frequently mutated ...
Source: Molecular Cancer Research - February 29, 2016 Category: Cancer & Oncology Authors: Peck, B., Maguire, S., Morrison, E., Wai, P., Natrajan, R. Tags: Tumor Heterogeneity (Intratumor and Intertumoral): Oral Presentations - Proffered Abstracts Source Type: research

Abstract A35: WNT4 signaling mediates endocrine response and resistance in invasive lobular carcinoma cells
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer, affecting ~30,000 U.S. women annually. Over 90% of ILC are estrogen receptor (ER)-positive, however, endocrine therapy may have poorer efficacy in a subset of ILC patients compared to invasive ductal carcinoma (IDC) patients. Based on these observations, we assessed genome-wide ER-mediated gene expression and ER genomic binding in ILC cell lines MDA MB 134VI (MM134) and SUM44PE (44PE), to identify novel mediators of ER signaling and putative therapeutic targets specifically in ILC.Among ILC-specific estrogen-regulated genes, the most strongly indu...
Source: Molecular Cancer Research - February 29, 2016 Category: Cancer & Oncology Authors: Sikora, M. J., Bahreini, A., Alexander, C. M., Oesterreich, S. Tags: Luminal Breast Cancer: Poster Presentations - Proffered Abstracts Source Type: research

Abstract P3-04-02: Invasive lobular carcinoma cell lines utilize WNT4 signaling to mediate estrogen-induced growth
Invasive lobular carcinoma (ILC) is a histological subtype of breast cancer representing 10-15% of newly diagnosed breast tumors. Over 90% of ILC are estrogen receptor (ER)-positive, however, endocrine response and estrogen signaling are not well understood in ILC. Retrospective analyses suggest that ILC patients treated with endocrine therapy have poorer outcomes than invasive ductal carcinoma (IDC) patients, and that ILC patients may not benefit from adjuvant tamoxifen. Based on these observations, we hypothesize that ER regulates unique signaling pathways in ILC cells that control growth and endocrine response.To identi...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Sikora, M., Oesterreich, S. Tags: Poster Session Abstracts Source Type: research

Abstract 1265: LAMP2 overexpression in the plasma membrane of breast cancer cells in response of chronic acidosis as a new imaging and therapeutic target
A combination of poor vasculature perfusion, hypoxia, and increased flux of carbons through fermentative glycolysis lead to extracellular acidosis in solid tumors; with extracellular pH values as low as 6.5. The proton concentration increases within the lumen due to diffusion limitations and increased production of acid from hypoxic-glycolytic cells, causing the interior of the lumen to become highly acidic. The glycolytic phenotype can become “hardwired” as Warburg proposed, leading to the continued generation of metabolic acids even in well-oxygenated conditions. This acidified habitat is constant and imparts a Darwi...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Damaghi, M., Sprung, R., Tafreshi, N., Estrella, V., Koomen, J., Morse, D., Gillies, R. Tags: Molecular and Cellular Biology Source Type: research